This week, we continue our Pancreatic Cancer series with the setting where most of our patients live: metastatic disease. Using our case of a patient with newly diagnosed metastatic pancreatic cancer, we trace how first-line chemotherapy evolved from single-agent gemcitabine to FOLFIRINOX, gemcitabine/nab-paclitaxel, and NALIRIFOX, then work through how to p ... Show More
Oct 14
Episode 167: Pancreatic Cancer Series, Pt. 2 – Resectable Disease
This week our pancreatic cancer series moves from diagnosis to management, starting with resectable disease. Using the case of a 68-year-old man with a 2.8 cm adenocarcinoma of the pancreatic head, we define what "resectable" actually means, review the operation and the goal of a ... Show More
26m 23s
Oct 7
Episode 166: Pancreatic Cancer Series, Pt. 1 – Biology, Diagnosis, and Staging
This week we kick off a brand-new series on pancreatic cancer, starting with the fundamentals. Using the case of a 68-year-old man with painless jaundice, weight loss, and new-onset diabetes, we cover the epidemiology and sobering survival statistics of pancreatic ductal adenocar ... Show More
28m 52s
Aug 2025
S2 Episode 1: Managing Side Effects and Maximizing Quality of Life in Multiple Myeloma Patients
Joseph Mikhael, MD, and Surbhi Sidana, MD, discuss the importance of balancing treatment intervals, managing side effects, and maximizing quality of life in multiple myeloma patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.c ... Show More
23m 58s
May 2022
S1 Episode 2: Frontline Therapy for Multiple Myeloma
Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/view ... Show More
23m 37s
Sep 2025
S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ... Show More
24m 38s